Context Therapeutics amends ATM agreement to increase offering capacity to up to $75M

Context Therapeutics Inc.

Prior ATM: sold 14.7M shares for ~$15M through Dec 2, 2024 to Oct 24, 2025.
Amendment raises aggregate offering to $75M (excl. prior sales) under new S-3 effective Nov 14, 2024.
New prospectus supplement dated Oct 24, 2025; agent Leerink commission up to 3% of gross proceeds.
Proceeds intended for R&D, working capital, and general corporate purposes.
Prior ATM prospectus terminated; no further sales under that facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.